Absci Runs AI Antibody Design and Molecular Dynamics on Oracle Cloud Infrastructure With AMD

Absci announced in September 2025, in a joint release with Oracle and AMD, that it runs its AI-driven drug discovery on Oracle Cloud Infrastructure (OCI) with AMD processors and GPUs. Absci, a clinical-stage biotech company advancing novel therapeutics with generative AI, selected Oracle Cloud Infrastructure as the technical foundation for developing AI models and scaling AI workflows. OCI bare metal instances powered by 5th Generation AMD EPYC processors and ultrafast RDMA cluster networking give Absci the low-latency networking and throughput needed for large-scale model training and high-resolution molecular-dynamics simulations that refine antibody-antigen interactions. With direct bare-metal access to AMD GPUs in a single flat-network supercluster, Absci has eliminated hypervisor overhead, reduced inter-GPU latency to as little as 2.5 microseconds, and benefits from terabytes-per-second throughput for checkpointing and data streaming. The collaboration is building on Absci success with OCI and partnering with AMD to further boost performance and scalability of its AI Drug Creation Platform with AMD next-generation Instinct MI355X GPUs. Absci CEO Sean McClain stated that the partnership pairs cutting-edge AI models with best-in-class infrastructure to accelerate the ability to bring novel therapeutics to patients while laying the technical foundation for next-generation AI-powered drug-discovery workflows.